Abstract: The invention relates to a method for predicting the efficacy of a cancer immunotherapy of an individual with respect to clinical benefit, which comprises the following steps: —providing a blood sample of said individual, —(a1) determining the number of lymphocytes in the blood of said individual, and/or (a2) determining the number of neutrophils in the blood of said individual, and —(b1) identifying the individual as having a predictive clinical benefit from the immunotherapy, if the number Of lymphocytes is below or equal to a lymphocyte baseline level of 1.4 to 1.8×109 per liter blood, especially below or equal to 1.6×109 per liter blood; or (b2) identifying the individual as having a predictive clinical benefit from the immunotherapy, if the number of neutrophils is below or equal to a neutrophil baseline level of from 4.0 to 6.0×109 per liter blood, especially below or equal to 5.

Abstract: The invention relates to a method for predicting the efficacy of a cancer immunotherapy of an individual with respect to clinical benefit, which comprises the following steps: —providing a blood sample of said individual, —(a1) determining the number of lymphocytes in the blood of said individual, and/or (a2) determining the number of neutrophils in the blood of said individual, and —(b1) identifying the individual as having a predictive clinical benefit from the immunotherapy, if the number Of lymphocytes is below or equal to a lymphocyte baseline level of 1.4 to 1.8×109 per liter blood, especially below or equal to 1.6×109 per liter blood; or (b2) identifying the individual as having a predictive clinical benefit from the immunotherapy, if the number of neutrophils is below or equal to a neutrophil baseline level of from 4.0 to 6.0×109 per liter blood, especially below or equal to 5.

Abstract: Described is a method for identifying the prognosis for improved clinical benefit of an individual suffering from a tumor comprising providing a blood sample of said individual, (a1) determining the number of lymphocytes in the blood of said individual, and/or (a2) determining the number of neutrophils in the blood of said individual, and (b1) identifying the individual as having a good prognosis for improved clinical benefit, if the number of lymphocytes is above a lymphocyte baseline level of 1.4 to 1.8×109 per liter blood, especially above 1.6×109 per liter blood; or (b2) identifying the individual as having a good prognosis for improved clinical benefit, if the number of neutrophils is below or equal to a neutrophil baseline level of from 4.0 to 6.0×109 per liter blood, especially below or equal to 5.